XLO - Multiplikator Forward P/S Xilio Therapeutics

Lambang korporat lan logo Xilio (XLO)

The projected P/S of Xilio Therapeutics, Inc. (XLO) visualizes the impact of currency factors on business valuation, while 1.00 shows the current value of the metric. Xilio Therapeutics, Inc. (XLO) is developing advanced cytokines that are activated within tumors. The brand's scientific authority is based on the creation of precise immuno-oncology agents. The operating model relies on external contractors for manufacturing and conducting all clinical trials.

XLO Xilio: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 10.08.2024 - 16.11.2026

Rincian analitis perusahaan Xilio Therapeutics (XLO)

- rega pasar lan target rega analis:
Ringkesan analisis perusahaan:Xilio XLO
Produk sing diprodhuksi xiliotx.com

The assessment of Xilio Therapeutics, Inc. (XLO) resilience to market downturns relies on cost optimization through outsourcing production to CDMO facilities, which minimizes capital risks. By analyzing the projected P/S multiple, an investor compares current market capitalization with forecasted revenue to determine the premium paid for future successes in oncobiotechnology and to evaluate the fairness of the market consensus regarding the business valuation.

Analisis pesaing

Multiplikator Forward P/S ONC (BeiGene Oncology)|Multiplikator Forward P/S Halozyme Corp HALO|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Group (AAPG) - Multiplikator forward rega marang pendapatan|CG Oncology Therapeutics (CGON) - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan UroGen Pharma URGN|Rasio rega marang prakiraan pendapatan Bicara Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Personalis Genomics PSNL|Multiplikator Forward P/S ERAS|Rasio rega marang pendapatan sing dikarepake DCTH|Y-mAbs Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Aura Biosciences Inc (AURA)|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc.)|SLS: Multiplikator Forward P/S|ACTU: Rasio rega marang pendapatan sing dikarepake|CTOR (Citius Oncology Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep tuhurabio.com HURA|Multiplikator Forward P/S TARA|FATE: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S WHWK (Aadi Bioscience)|TCRX (TScan) - Rega mangsa ngarep marang pendapatan|Champions Oncology, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake XBiotech Inc XBIT|CVM: Multiplikator Forward P/S|OSTX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Radiopharm Theranostics Limited|Multiplikator Forward P/S artivabio.com|Multiplikator forward rega marang pendapatan ANL (Adlai Nortye Limited)|Veru - Kapitalisasi marang prakiraan pendapatan|Tempest Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Enochian BioSciences - Rasio rega marang prakiraan pendapatan|Mural Oncology - Multiplikator Forward P/S|KAPA - Multiplikator Forward P/S|OnKure Therapeutics Inc (OKUR) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan CytoMed|Rasio rega marang prakiraan pendapatan curis.com|Multiplikator forward rega marang pendapatan Apollomics, Inc. (APLM)|Multiplikator Forward P/S THAR|Advanced Biomed Corp - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Genprex GNPX|Rasio kapitalisasi marang dodolan sing dikarepake Calidi Bio (CLDI)|sunshinebiopharma.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep xeneticbio.com|salariuspharma.com (SLRX) - Rasio rega marang prakiraan pendapatan|Purple Biotech Ltd. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan AON|Multiplikator Forward P/S BeiGene Ltd.|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|Multiplikator forward rega marang pendapatan Elevation Oncology, Inc. ELEV|Multiplikator Forward P/S ICAD (iCAD Inc.)|IKNA - Multiplikator forward rega marang pendapatan|NTBL: Multiplikator forward rega marang pendapatan|viracta.com (VIRX) - Multiplikator forward rega marang pendapatan|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Corp (NAYA) - Multiplikator Forward P/S|AAPGV (Ascentage) - Multiplikator Forward P/S